Convention on Biodiverstiy Archives • GeneConvene Virtual Institute

Convention on Biodiverstiy

Engineered Gene Drives

35221
Convention on Biological Diversity, 2025-10-05 20:11:01.
This page is dedicated to living modified organisms containing engineered gene drives and was developed further to decision CP-10/10 of the Conference of the Parties serving as a meeting of the Parties to the Cartagena Protocol on Biosafety (COP-MOP).

Convention on Biological Diversity Process

34382
GeneConvene Global Collaborative, 2023-04-11 13:11:27.
The image describes organizational elements and hierarchy within the United Nations system to situate the activities undertaken for the implementation of the Convention on Biological Diversity (CBD, effective Dec 1993) and its supplementary treaty the Cartagena Protocol on Biosafety to the CBD (effective Sept 2003). It also outlines the two yearly cycle of events and workflow via meetings such as the COP (Conference of the Parties) and MOP (Meeting of the Parties) organized by the CBD Secretariat to support representatives of Parties, non-Parties, non-governmental organizations and other associated organizations, and observers to discuss past work and establish future areas/programs of work related to the implementation of the treaties.

GeneConvene Global Collaborative Webinar Series | Demystifying the Convention on Biological Diversity – Seven Videos

21940
Hector Quemada and David O'Brochta, GeneConvene Global Collaborative, 2022-04-28 12:39:49.
The Convention on Biological Diversity (CBD) is an international agreement aimed at providing the legal framework for country cooperation to conserve biodiversity, while also enabling its sustainable use, and providing for fair and equitable sharing of the benefits derived from that use. It became effective in 1993 when the first 30 countries signed it, but now has 196 parties. Biotechnology figures prominently in this agreement, since one of its major goal is to "promote and advance priority access on a fair and equitable basis by Contracting Parties, especially developing countries, to the results and benefits arising from biotechnologies." The CBD provides the basis for regulations on biotechnologies, particularly genetically engineered organisms (including gene drive organisms). While the convention, and its subsidiary agreements, have a significant impact on the regulatory environment within which synthetic gene drive research takes place, the procedures and decision-making processes connected with the CBD are often not transparent to researchers and others who do not closely follow the proceedings.